US$ 23.50
ascendis pharma glp-1 receptor agonist medications Agonists: An Alternative for Rapid-Acting Insulin? List of approved and pending
Description
Nowak, M., Nowak, W

Triple receptor agonists have the potential to further bridge the efficacy gap in WL between BS and the currently approved obesity pharmacotherapies, with the added potential for other synergistic metabolic benefits, such as improving glycaemia in people with T2D, and treating or preventing MASLD/MASH

Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes

Retrieved 18 January 2023

Please refer to the solubility information to select the appropriate solvent
